Anavex Life Sciences Corp (AVXL)

[Doc328]

Whenever a Biotech CEO speaks, I am skeptical.

I wrote a post right after the CC about safety visits at the end of a trial. They are common and known in advance.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173304277

Here is alink to the 182 girl P3 trofinetide study protocol that has been published. You will see that a 30 day safety visit was built in. This is clearly what Missling is talking about. Analysis of efficacy does not need to wait for the safety visit which is why most companies still get data out 10-12 weeks after the lat treatment visit. Data scrubbing does not wait for the end of the study but is a continuous process.

CM: Yes, after the last 12-week readout, there was an additional safety follow-up and that's basically why the timing is maybe a little bit different from expectations, but we are on track to release this data once we have it.

I love this quote: "that's basically why the timing is maybe a little bit different from expectations" He set the expectation multiple times. He knows the protocol visit schedule. And "but we are on track to release this data once we have it" He has never been on track for anything.